Nutriband (NTRB) Competitors

Nutriband logo
$4.90 -0.10 (-1.90%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$4.90 0.00 (0.00%)
As of 11/20/2026 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NTRB vs. CGC, BIOA, AMRN, VNDA, and LFCR

Should you buy Nutriband stock or one of its competitors? Nutriband's main competitors and comparable companies include Canopy Growth (CGC), BioAge Labs (BIOA), Amarin (AMRN), Vanda Pharmaceuticals (VNDA), and Lifecore Biomedical (LFCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Nutriband compare to Canopy Growth?

Nutriband (NASDAQ:NTRB) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Nutriband has higher earnings, but lower revenue than Canopy Growth. Nutriband is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nutriband$2.04M29.24-$8.23M-$0.53N/A
Canopy Growth$308.32M0.59-$190.29M-$0.51N/A

Nutriband has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

19.7% of Nutriband shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 0.4% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Canopy Growth has a net margin of -73.03% compared to Nutriband's net margin of -430.35%. Canopy Growth's return on equity of -28.21% beat Nutriband's return on equity.

Company Net Margins Return on Equity Return on Assets
Nutriband-430.35% -109.07% -95.54%
Canopy Growth -73.03%-28.21%-17.97%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nutriband
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Canopy Growth
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Nutriband had 2 more articles in the media than Canopy Growth. MarketBeat recorded 3 mentions for Nutriband and 1 mentions for Canopy Growth. Nutriband's average media sentiment score of 0.68 beat Canopy Growth's score of 0.42 indicating that Nutriband is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nutriband
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Canopy Growth
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Canopy Growth beats Nutriband on 8 of the 15 factors compared between the two stocks.

How does Nutriband compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

BioAge Labs currently has a consensus price target of $29.00, suggesting a potential upside of 577.57%. Given BioAge Labs' stronger consensus rating and higher possible upside, research analysts plainly believe BioAge Labs is more favorable than Nutriband.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Nutriband
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BioAge Labs has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Nutriband has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

Nutriband has a net margin of -430.35% compared to BioAge Labs' net margin of -1,253.60%. BioAge Labs' return on equity of -31.42% beat Nutriband's return on equity.

Company Net Margins Return on Equity Return on Assets
BioAge Labs-1,253.60% -31.42% -29.59%
Nutriband -430.35%-109.07%-95.54%

In the previous week, BioAge Labs had 3 more articles in the media than Nutriband. MarketBeat recorded 6 mentions for BioAge Labs and 3 mentions for Nutriband. Nutriband's average media sentiment score of 0.68 beat BioAge Labs' score of 0.01 indicating that Nutriband is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAge Labs
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nutriband
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

19.7% of Nutriband shares are held by institutional investors. 17.6% of BioAge Labs shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nutriband has lower revenue, but higher earnings than BioAge Labs. Nutriband is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAge Labs$8.99M21.88-$80.61M-$2.55N/A
Nutriband$2.04M29.24-$8.23M-$0.53N/A

Summary

Nutriband beats BioAge Labs on 8 of the 15 factors compared between the two stocks.

How does Nutriband compare to Amarin?

Amarin (NASDAQ:AMRN) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Amarin has a net margin of -10.87% compared to Nutriband's net margin of -430.35%. Amarin's return on equity of -0.52% beat Nutriband's return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-10.87% -0.52% -0.36%
Nutriband -430.35%-109.07%-95.54%

Amarin presently has a consensus price target of $13.00, suggesting a potential upside of 22.99%. Given Amarin's stronger consensus rating and higher probable upside, equities analysts plainly believe Amarin is more favorable than Nutriband.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33
Nutriband
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Amarin had 1 more articles in the media than Nutriband. MarketBeat recorded 4 mentions for Amarin and 3 mentions for Nutriband. Nutriband's average media sentiment score of 0.68 beat Amarin's score of -0.03 indicating that Nutriband is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nutriband
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amarin has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Nutriband has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

22.3% of Amarin shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nutriband has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$213.65M1.04-$38.80M-$0.96N/A
Nutriband$2.04M29.24-$8.23M-$0.53N/A

Summary

Amarin beats Nutriband on 8 of the 15 factors compared between the two stocks.

How does Nutriband compare to Vanda Pharmaceuticals?

Nutriband (NASDAQ:NTRB) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Vanda Pharmaceuticals has a consensus target price of $13.50, indicating a potential upside of 292.44%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Nutriband.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nutriband
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Vanda Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Nutriband has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nutriband has higher earnings, but lower revenue than Vanda Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nutriband$2.04M29.24-$8.23M-$0.53N/A
Vanda Pharmaceuticals$216.10M0.96-$220.47M-$4.62N/A

Vanda Pharmaceuticals has a net margin of -119.87% compared to Nutriband's net margin of -430.35%. Vanda Pharmaceuticals' return on equity of -62.70% beat Nutriband's return on equity.

Company Net Margins Return on Equity Return on Assets
Nutriband-430.35% -109.07% -95.54%
Vanda Pharmaceuticals -119.87%-62.70%-37.53%

In the previous week, Nutriband had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 3 mentions for Nutriband and 2 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.89 beat Nutriband's score of 0.68 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nutriband
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vanda Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Vanda Pharmaceuticals beats Nutriband on 9 of the 15 factors compared between the two stocks.

How does Nutriband compare to Lifecore Biomedical?

Nutriband (NASDAQ:NTRB) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

In the previous week, Nutriband had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Nutriband and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.02 beat Nutriband's score of 0.68 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nutriband
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lifecore Biomedical
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nutriband has higher earnings, but lower revenue than Lifecore Biomedical. Nutriband is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nutriband$2.04M29.24-$8.23M-$0.53N/A
Lifecore Biomedical$128.87M1.88-$70.51M-$1.86N/A

Nutriband has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 1.72%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than Nutriband.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nutriband
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lifecore Biomedical
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

Lifecore Biomedical has a net margin of -56.80% compared to Nutriband's net margin of -430.35%. Lifecore Biomedical's return on equity of 0.00% beat Nutriband's return on equity.

Company Net Margins Return on Equity Return on Assets
Nutriband-430.35% -109.07% -95.54%
Lifecore Biomedical -56.80%N/A -29.53%

Summary

Lifecore Biomedical beats Nutriband on 9 of the 15 factors compared between the two stocks.

Get Nutriband News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTRB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NTRB vs. The Competition

MetricNutribandPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$59.81M$13.12B$7.44B$10.86B
Dividend YieldN/A2.62%2.51%4.58%
P/E Ratio-9.2527.8232.5628.63
Price / Sales36.867.297.745.15
Price / CashN/A15.2220.2520.77
Price / Book8.925.164.343.51
Net Income-$8.23M$2.86B$3.51B$394.12M
7 Day Performance-19.59%-7.27%-8.07%-8.97%
1 Month Performance-15.58%-9.60%-10.29%-11.61%
1 Year Performance2.62%-9.28%-4.70%-11.21%

Nutriband Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NTRB
Nutriband
0.8837 of 5 stars
$4.91
-1.9%
N/A+2.6%$59.81M$1.62MN/A3
CGC
Canopy Growth
0.8352 of 5 stars
$0.59
-4.9%
N/A-61.5%$279.82M$251.01MN/A1,128
BIOA
BioAge Labs
2.6896 of 5 stars
$5.78
+1.6%
$33.00
+470.9%
-50.5%$261.15M$8.60MN/A62
AMRN
Amarin
1.9003 of 5 stars
$11.75
+0.1%
$13.00
+10.6%
-35.5%$247.98M$213.65MN/A80
VNDA
Vanda Pharmaceuticals
4.08 of 5 stars
$4.08
-0.2%
$13.50
+230.9%
-28.3%$247.32M$216.10MN/A533

Related Companies and Tools


This page (NASDAQ:NTRB) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners